Translating Cancer Research to Patients

Leap Therapeutics’ current clinical program includes product candidates targeting esophageal cancer, a form of bile duct cancer known as cholangiocarcinoma, and other solid tumor malignancies. Details on our clinical trials are summarized below.

Therapeutic Candidate Target Trial Link Trial Description
Leap Therapeutics Clinical Trials
DKN-01 DKK1 NCT02013154

Study of DKN-01 in Combination with Paclitaxel in Patients with Refractory/recurrent Esophageal or Gastro-esophageal Junction Cancer

DKN-01 DKK1 NCT02375880

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

TRX518 GITR NCT01239134 Study of TRX518 in Stage III or IV Malignant Melanoma or Other Solid Tumors 
TRX518 GITR NCT02628574 Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors